Back to top
more

Becton, Dickinson and Company (BDX)

(Real Time Quote from BATS)

$233.02 USD

233.02
569,905

-0.23 (-0.10%)

Updated Sep 6, 2024 02:38 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 32% (170 out of 251)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Based in Franklin Lakes, NJ, Becton, Dickinson and Company (BDX) commonly known as BD, is a medical technology company engaged principally in the development, manufacture and sale of medical devices, instrument systems and reagents. In fiscal 2019, BD’s revenues increased 8.2% to $17.29 billion. Earlier, BD’s operations consisted of three business segments: BD Medical, BD Diagnostics and BD Biosciences. However, the company’s organizational structure was realigned to form two principal business segments: BD Medical, BD Life Sciences and BD Interventional.

BD's (BDX) Latest Collaboration to Enhance Patient Care

by Zacks Equity Research

BD's (BDX) new partnership is expected to increase efficiency for new clinical trials, generate evidence, support new claims for its products and streamline medical device regulatory submissions.

Why Is Dentsply (XRAY) Up 6.2% Since Last Earnings Report?

by Zacks Equity Research

Dentsply (XRAY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

BD's (BDX) New Tie-Up to Develop Detection Kit for Monkeypox

by Zacks Equity Research

BD's (BDX) partnership with CerTest is expected to aid in advancing the understanding of the monkeypox virus' global spread.

BD (BDX) to Expand Base in Pharmacy Automation With New Buyout

by Zacks Equity Research

BD's (BDX) buyout of Parata Systems is expected to advance its 2025 strategy to accelerate innovation in smart, connected care and enabling new care settings.

BD's (BDX) Latest Product to Transform Research Outcome

by Zacks Equity Research

BD's (BDX) latest cell sorting technology is expected to speed up the process of cell sorting as well as provide answers to previously unthinkable questions.

New Strong Sell Stocks for May 27th

by Zacks Equity Research

ACER, BBWI, and BDX have been added to the Zacks Rank #5 (Strong Sell) List on May 27, 2022.

New Strong Sell Stocks for May 25th

by Zacks Equity Research

ALGN, AUD, and BDX have been added to the Zacks Rank #5 (Strong Sell) List on May 25, 2022.

BD (BDX) Introduces New Molecular Diagnostic Platform in US

by Zacks Equity Research

BD's (BDX) new fully-automated, high-throughput infectious disease molecular diagnostics platform in the United States to aid lab technicians in prioritizing higher value work.

BD (BDX) Extends Partnership to Boost Diagnostic Blood Collection

by Zacks Equity Research

BD (BDX) expands strategic partnership with Babson Diagnostics that will enable less invasive blood sample collection easier and patient-centric.

New Strong Sell Stocks for May 13th

by Zacks Equity Research

DDD, AMRN, and BDX have been added to the Zacks Rank #5 (Strong Sell) List on May 13, 2022.

Company News for May 6, 2022

by Zacks Equity Research

Companies In The News Are: SHOP, WRK, BDX, ALB.

BD (BDX) Beats on Q2 Earnings and Revenues, Revises FY22 View

by Zacks Equity Research

The majority of BD's (BDX) core units witness strong revenue growth in the fiscal second quarter.

Becton Dickinson (BDX) Q2 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Becton Dickinson (BDX) delivered earnings and revenue surprises of 6.71% and 3.12%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Why Becton (BDX) Might Surprise This Earnings Season

by Zacks Equity Research

Becton (BDX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Becton Dickinson (BDX) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

by Zacks Equity Research

Becton Dickinson (BDX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

BD (BDX) Gears Up for Q2 Earnings: What's in the Offing?

by Zacks Equity Research

Continued strength in BD's (BDX) Interventional segment is expected to have driven up Q2 sales.

Why Becton Dickinson (BDX) is Poised to Beat Earnings Estimates Again

by Zacks Equity Research

Becton Dickinson (BDX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Antares Pharma (ATRS) Moves 49.2% Higher: Will This Strength Last?

by Zacks Equity Research

Antares Pharma (ATRS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

The Zacks Analyst Blog Highlights Becton Dickinson, Phibro Animal Health, McKesson, and UnitedHealth Group

by Zacks Equity Research

Becton Dickinson, Phibro Animal Health, McKesson, and UnitedHealth Group are part of top Analyst Blog.

AngioDynamics (ANGO) Q3 Earnings Top Estimates, Revenues Lag

by Zacks Equity Research

AngioDynamics (ANGO) registers strong revenue growth in its Med Tech business as well as domestic revenues in third-quarter fiscal 2022.

Riya Anand headshot

Bet on These 4 Low-Beta, High-Dividend MedTech Stocks for 2022

by Riya Anand

Stocks like Becton, Dickinson and Company (BDX), Phibro Animal Health (PAHC), McKesson Corporation (MCK) and UnitedHealth Group Inc (UNH) are right picks with strong fundamentals.

Here's How Much a $1000 Investment in Becton Dickinson Made 10 Years Ago Would Be Worth Today

by Zacks Equity Research

Investing in certain stocks can pay off in the long run, especially if you hold on for a decade or more.

Is Aileron Therapeutics, Inc. (ALRN) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Aileron Therapeutics, Inc. (ALRN) and Becton Dickinson (BDX) have performed compared to their sector so far this year.

The Zacks Analyst Blog Highlights Owens & Minor, Thermo Fisher Scientific, Medtronic and Becton, Dickinson and Co.

by Zacks Equity Research

Owens & Minor, Thermo Fisher Scientific, Medtronic and Becton, Dickinson and Co. have been included in this Analyst Blog.

Here's Why You Should Retain BD (BDX) Stock in Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about BD (BDX) owing to its slew of product launches and strategic deals.